Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Braga – page 56

684 clinical trials in Braga, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Braga at a glance
684
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

684 trials in Braga

Open in trial search

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Hormone receptor positive breast cancer+1

Not recruiting

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Antipsychotics
  • Sponsor:Gilead Sciences Inc.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer

Not recruiting

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Systemic lupus erythematosus

Not recruiting

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not recruiting

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Bronchopulmonary dysplasia

Not recruiting

Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Mecasermin Rinfabate
  • Sponsor:Ohb Neonatology Limited

Plasma cell myeloma refractory

Not recruiting

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Braga

What the registry says about research in the country

01 Neurological Conditions

Innovative trials exploring treatments for multiple sclerosis, including chronic neuropathic pain management and new therapeutic approaches. Research also encompasses frontotemporal dementia and various types of migraines.

  • Multiple Sclerosis Treatment
  • Neuropathic Pain Management
  • Menstrual Migraine Prevention

Studies focus on both symptom management and disease modification approaches.

02 Dermatological Studies

Comprehensive research into various skin conditions, including plaque psoriasis, atopic dermatitis, and hidradenitis suppurativa. Clinical trials are evaluating new biological treatments and long-term management strategies.

  • Psoriasis Management
  • Eczema Treatment
  • Inflammatory Skin Conditions

Focus on developing targeted therapies for chronic skin conditions.

03 Immunological Disorders

Investigation of novel treatments for autoimmune conditions, including studies on lupus nephritis and immune thrombocytopenia. Research aims to develop more effective therapeutic approaches.

  • Autoimmune Disease Management
  • Immunotherapy Development
  • Blood Disorder Treatment

Emphasis on innovative immunological interventions and targeted therapies.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.